Chai Discovery signs AI antibody design licensing deal with Pfizer

Chai Discovery’s licensing deal with Pfizer is another sign that frontier bio‑AI is sliding from demo status into core pharmaceutical infrastructure. Chai claims Chai‑3 doubles the success rate of its previous AI‑driven antibody designs and can compress early discovery cycles from months or years into weeks. Giving one of the world’s biggest drugmakers early access, plus a model tuned on Pfizer’s internal data, effectively plugs a frontier‑grade AI copilot directly into high‑value wet‑lab pipelines. For the broader race to AGI, this matters on two fronts. First, it validates the economic case for domain‑specialist models that are deeply embedded in real workflows rather than general chatbots. Revenue from elite enterprise customers like Pfizer can fund ever‑larger, more capable scientific models—systems that are powerful reasoning engines in their own right. Second, it intensifies competitive pressure on other pharmas and bio‑AI startups to secure comparable tooling. If Chai’s claims about 100‑fold improvements over legacy computational methods continue to hold up in production, the bar for “serious” AI in drug discovery has just moved sharply upward.